Patent: 10,004,808
✉ Email this page to a colleague
Summary for Patent: 10,004,808
| Title: | Methods of treating ulcerative colitis |
| Abstract: | Methods for inducing clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human .alpha.4.beta.7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-.alpha.4.beta.7 antibody in vivo. |
| Inventor(s): | Fox; Irving H. (Wellesley, MA), Scholz; Catherine (Woburn, MA) |
| Assignee: | MILLENNIUM PHARMACEUTICALS, INC. (Cambridge, MA) |
| Application Number: | 15/215,000 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,004,808
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.s.a., Inc. | ENTYVIO | vedolizumab | For Injection | 125476 | 05/20/2014 | ⤷ Try a Trial | 2031-05-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
